Selective versus nonselective beta adrenoceptor antagonists in hypertension.

abstract：:A systematic review of dementia cost-of-illness (COI) studies in the US and Canada was conducted to explore the policy-making relevance of these studies. MEDLINE, CINAHL, EconLit, AMED and the Cochrane Library were searched from inception to March 2010 for English-language COI articles. Content analysis was used to ex...

journal_title：PharmacoEconomics

authors： Oremus M,Aguilar SC

更新日期：2011-02-01 00:00:00

abstract：BACKGROUND:Pharmaceuticals are usually granted a marketing authorisation on the basis of randomised controlled trials (RCTs). Occasionally the efficacy of a treatment is assessed without a randomised comparator group (either active or placebo). OBJECTIVE:To identify and develop a taxonomic account of economic modellin...

journal_title：PharmacoEconomics

authors： Hatswell AJ,Freemantle N,Baio G

更新日期：2017-02-01 00:00:00

abstract：:A survey of the prescribing of psychotropic drugs was carried out at the Psychiatric Hospital of Bahrain. This retrospective study on 60 inpatients of the Long Stay Ward revealed a man:woman ratio of 2.7. 91% of the men and 88% of the women were over 40 years old. 44 of the 60 patients had a diagnosis of schizophre...

journal_title：PharmacoEconomics

authors： El Hefny F,Al Haddad MK,Mathur V

更新日期：1992-03-01 00:00:00

abstract：BACKGROUND:There is evidence that the earlier a patient reaches hospital and receives thrombolysis, the better the outcome. The GREAT (Grampian Region Early Anistreplase Trial) directly addressed the issue of early thrombolysis by evaluating, in a randomised controlled trial, the efficacy of thrombolysis in the communi...

journal_title：PharmacoEconomics

authors： Vale L,Steffens H,Donaldson C

更新日期：2004-01-01 00:00:00

abstract：:This tutorial presents practical guidance on transforming various types of information published in journals, or available online from government and other sources, into transition probabilities for use in state-transition models, including cost-effectiveness models. Much, but not all, of the guidance has been previou...

journal_title：PharmacoEconomics

authors： Gidwani R,Russell LB

更新日期：2020-11-01 00:00:00

abstract：:Germany is in a period of transition with regard to healthcare reform. The number and intensity of cost control interventions increased during the last decade in an attempt to contain healthcare expenditure. The German legislature has implemented long term macroeconomic measures such as contribution rate stability and...

journal_title：PharmacoEconomics

authors： Ulrich V,Wille E

更新日期：1996-01-01 00:00:00

abstract：BACKGROUND:The apparent decrease in the rate of approval of new molecular entities has provoked extensive discussion and fears that the productivity of biopharmaceutical research and development has severely declined in recent years. OBJECTIVE:To investigate the extent to which traditional measures of innovative outpu...

journal_title：PharmacoEconomics

authors： Berndt ER,Cockburn IM,Grépin KA

更新日期：2006-12-01 00:00:00

abstract：:Clinical studies have shown that the combination of an inhaled corticosteroid (ICS) and a long-acting beta(2)-adrenoceptor agonist (LABA) for patients with asthma is more effective than the use of ICS alone in equivalent or higher doses, as well as the use of other combinations. However, the relatively higher acquisit...

journal_title：PharmacoEconomics

authors： Akazawa M,Stempel DA

更新日期：2006-01-01 00:00:00

abstract：:Epidural analgesia and intravenous analgesia with opioids are two techniques for providing pain relief for women in labour. Labour pain is comparable to surgical pain in its severity, and epidural analgesia provides better relief from this pain than intravenous analgesia; a meta-analysis quantified this improvement to...

journal_title：PharmacoEconomics

authors： Huang C,Macario A

更新日期：2002-01-01 00:00:00

abstract：:Stroke remains the leading cause of neurological disability and the third leading cause of death worldwide, consuming a large share of total healthcare expenditures. In this review, we discuss the cost effectiveness of stroke prevention for various risk factor-modification programmes and pharmacological interventions ...

journal_title：PharmacoEconomics

authors： Alexandrov AV,Smurawska LT,Bartle W,Oh P

更新日期：1997-05-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to examine the cost effectiveness of fluvoxamine compared with tricyclic antidepressants (TCAs) in the treatment of patients with depressive episodes. DESIGN AND SETTING:A Markov process model was constructed to model the effectiveness, as measured by time without depression, ...

journal_title：PharmacoEconomics

authors： Nuijten M,Hadjadjeba L,Evans C,van den Berg J

更新日期：1998-10-01 00:00:00

abstract：OBJECTIVE:To estimate savings in the cost of caring for patients with Alzheimer's disease (AD) during 6 months, 1 year and 2 years of treatment with rivastigmine. An intermediate objective was to estimate the relationship between disease progression and institutionalisation. DESIGN AND SETTING:We assessed the relation...

journal_title：PharmacoEconomics

authors： Hauber AB,Gnanasakthy A,Snyder EH,Bala MV,Richter A,Mauskopf JA

更新日期：2000-04-01 00:00:00

abstract：:Answering the demanding questions asked of pharmacotherapy in the 21st century will require more reliance on the disciplines of pharmacoepidemiology and pharmacoeconomics. Pharmacoepidemiology can help assess patterns and appropriateness of drug utilisation, provide explanations for poor compliance, quantify the frequ...

journal_title：PharmacoEconomics

authors： Avorn J

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:National EQ-5D value sets are developed because preferences for health may vary in different populations. UK values are lower than US values for most of the 243 possible EQ-5D health states. Although similar protocols were used for data collection, analytic choices regarding how to model values from the coll...

journal_title：PharmacoEconomics

authors： Augestad LA,Rand-Hendriksen K,Kristiansen IS,Stavem K

更新日期：2012-12-01 00:00:00

abstract：:This paper analyses the 32 technology appraisals completed by the National Institute for Clinical Excellence (NICE) in the UK from its establishment to the end of January 2002. It looks at why technologies have been rejected, what has happened to products reviewed at launch, evidence of rationing on cost-effectiveness...

journal_title：PharmacoEconomics

authors： Towse A,Pritchard C

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:The ARTEMIS trial compared first-line antiretroviral therapy (ART) with lopinavir/ritonavir (LPV/r) to darunavir plus ritonavir (DRV + RTV) for HIV-1-infected subjects. In order to fully assess the implications of this study, economic modelling extrapolating over a longer term is required. OBJECTIVE:The aim...

journal_title：PharmacoEconomics

authors： Simpson KN,Pei PP,Möller J,Baran RW,Dietz B,Woodward W,Migliaccio-Walle K,Caro JJ

更新日期：2013-05-01 00:00:00

abstract：BACKGROUND:Pharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines. Routine adoption of pharmacogenetic tests requires evidence of their cost effectiveness. OBJECTIVE:The present review aims to systematically review published ec...

journal_title：PharmacoEconomics

authors： Plumpton CO,Roberts D,Pirmohamed M,Hughes DA

更新日期：2016-08-01 00:00:00

abstract：BACKGROUND:Head and neck cancer (HNC) and its treatment can affect communication, nutrition, and physical appearance, and the global impact of this disease on patients' quality of life may be substantial. OBJECTIVE:The aim of this systematic literature review was to describe the impact of HNC and its treatment on the ...

journal_title：PharmacoEconomics

authors： Wissinger E,Griebsch I,Lungershausen J,Byrnes M,Travers K,Pashos CL

更新日期：2014-12-01 00:00:00

abstract：:Cost-effectiveness analysis (CEA) is one of the main tools of economic evaluation. Every CEA is based on a number of assumptions, some of which may not be accurate, introducing uncertainty. Sensitivity analysis (SA) formalizes ways to measure and evaluate this uncertainty. Specific sources of uncertainty in CEA have b...

journal_title：PharmacoEconomics

authors： Jain R,Grabner M,Onukwugha E

更新日期：2011-04-01 00:00:00

abstract：:Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, with an estimated prevalence rate in the general population of 10-15% in industrialised countries. Although IBS is not a life-threatening disease, it contributes significantly to a large segment of healthcare resource consu...

journal_title：PharmacoEconomics

authors： Maxion-Bergemann S,Thielecke F,Abel F,Bergemann R

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Health technology assessment has been increasingly used in China, having been legally mandated in 2019, to inform reimbursement decisions and price negotiations between the National Healthcare Security Administration and pharmaceutical companies around the price of new pharmaceuticals. The criteria currently...

journal_title：PharmacoEconomics

authors： Ochalek J,Wang H,Gu Y,Lomas J,Cutler H,Jin C

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:Over 200 million people have chronic obstructive pulmonary disease (COPD) worldwide. The number of disease-year equivalents and deaths attributable to COPD are high. Guidelines for the pharmacological treatment of the disease recommend an individualized step-up approach in which treatment is intensified when...

journal_title：PharmacoEconomics

authors： Rutten-van Mölken MP,Goossens LM

更新日期：2012-04-01 00:00:00

abstract：:For practical reasons, in order to carry out economic evaluations of collective decisions, total costs will generally be compared with total benefits; hence, individuals' willingness to pay (WTP) or quality-adjusted life-years (QALYs) have to be estimated at an aggregate level. So far, aggregation has usually been don...

journal_title：PharmacoEconomics

authors： Liljas B,Lindgren B

更新日期：2001-01-01 00:00:00

abstract：:Potential conflict between the goals of the investigators and the sponsors of pharmacoeconomic and clinical research has been well documented. Although there have been efforts to formalise relationships between sponsors and investigators in some areas of clinical research, no set of guidelines or standardised contract...

journal_title：PharmacoEconomics

authors： Schulman KA,Rubenstein LE,Glick HA,Eisenberg JM

更新日期：1995-03-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to estimate the per-patient-per-month (PPPM) costs of medications in the six Medicare Part D protected classes based on findings among Medicare and dual eligible beneficiaries with drug coverage before the enactment of the benefit. DESIGN:Data were from the Thomson Medstat Mar...

journal_title：PharmacoEconomics

authors： Mucha L,Masia NA,Axelsen KJ

更新日期：2006-01-01 00:00:00

abstract：:Epilepsy is a chronic condition with numerous social and psychological consequences. This work aimed to review available data on epilepsy and the impact of surgical and pharmaceutical treatments on the quality of life in adults and children. Research on quality of life in epilepsy is characterised by a wide and fragme...

journal_title：PharmacoEconomics

authors： Berto P

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Intensive insulin therapy improves glycosylated haemoglobin (Hb(A1C)) levels and delays the onset of long-term diabetes-related complications. Current treatment guidelines recommend maintaining a glycosylated haemoglobin (Hb(A1C)) of < or = 7% in patients with type 1 and 2 diabetes mellitus. Ho...

journal_title：PharmacoEconomics

authors： Grima DT,Thompson MF,Sauriol L

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Results from the PROVE IT trial suggest that patients with acute coronary syndrome (ACS) treated with atorvastatin 80 mg/day (A80) have significantly lower rates of cardiovascular events compared with patients treated with pravastatin 40 mg/day (P40). In a genetic post hoc substudy of the PROVE IT trial, the...

journal_title：PharmacoEconomics

authors： Parthan A,Leahy KJ,O'Sullivan AK,Iakoubova OA,Bare LA,Devlin JJ,Weinstein MC

更新日期：2013-06-01 00:00:00

abstract：BACKGROUND:Candidaemia and other forms of invasive candidiasis (C/IC) are serious and costly events for hospitalized patients, particularly those in the ICU. Both fluconazole and the echinocandins are recommended as first-line therapy for C/IC. Resource use and cost considerations are important in selecting appropriate...

journal_title：PharmacoEconomics

authors： Reboli AC,Rotstein C,Kett DH,Maschio M,Cartier S,Chambers R,Tarallo M

更新日期：2011-08-01 00:00:00

abstract：:In this paper we consider the evolving American healthcare landscape and what it means for the use of economic evaluation of health interventions. We emphasise that use of economic evaluation in the US is unlikely to follow the European, Canadian or Australian models, which use cost effectiveness openly and explicitly...

journal_title：PharmacoEconomics

authors： Neumann PJ,Sullivan SD

更新日期：2006-01-01 00:00:00